$SAVA
CASSAVA SCIENCES INC Stock $sava

$sava Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000143774924033944 Filed on November 07, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$12.95M	$4.280M
YoY Change		202.5%	51.83%
% of Gross Profit
Research & Development		$17.68M	$23.60M
YoY Change		-25.11%	27.4%
% of Gross Profit
Depreciation & Amortization		$228.0K	$273.0K
YoY Change		-16.48%	50.83%
% of Gross Profit
Operating Expenses		$30.62M	$27.88M
YoY Change		9.84%	30.61%
Operating Profit		-$30.62M	-$27.88M
YoY Change		9.84%	30.61%
Interest Expense		$2.618M	$2.005M
YoY Change		30.57%	128.36%
% of Operating Profit
Other Income/Expense, Net		$62.00K	$223.0K
YoY Change		-72.2%	6.19%
Pretax Income		-$27.94M	-$25.65M
YoY Change		8.94%	26.62%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings		-$27.94M	-$25.65M
YoY Change		8.94%	26.63%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.58	-$0.61
Diluted Earnings Per Share		-$0.58	-$0.61
COMMON SHARES
Basic Shares Outstanding	48.11M	47.98M	41.97M
Diluted Shares Outstanding		47.98M	42.00M

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$149.0M	$142.4M
YoY Change	4.62%	-18.47%
Cash & Equivalents	$149.0M	$142.4M
Short-Term Investments
Other Short-Term Assets	$192.0K	$189.0K
YoY Change	1.59%	-97.8%
Inventory
Prepaid Expenses
Receivables	$1.275M	$1.300M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$202.5M	$150.2M
YoY Change	34.87%	-18.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.14M	$22.08M
YoY Change	-4.27%	-4.55%
Goodwill
YoY Change
Intangibles	$69.00K	$268.0K
YoY Change	-74.25%	-63.78%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$21.20M	$22.35M
YoY Change	-5.11%	-6.95%
TOTAL ASSETS
Total Short-Term Assets	$202.5M	$150.2M
Total Long-Term Assets	$21.20M	$22.35M
Total Assets	$223.8M	$172.5M
YoY Change	29.69%	-16.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$52.24M	$9.500M
YoY Change	449.94%	168.82%
Accrued Expenses	$4.493M	$7.500M
YoY Change	-40.09%	83.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$57.03M	$17.41M
YoY Change	227.52%	109.61%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$80.00K	$0.00
YoY Change		-100.0%
Total Long-Term Liabilities	$80.00K	$0.00
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.03M	$17.41M
Total Long-Term Liabilities	$80.00K	$0.00
Total Liabilities	$57.11M	$17.41M
YoY Change	227.98%	103.27%
SHAREHOLDERS EQUITY
Retained Earnings	-$377.5M	-$359.9M
YoY Change	4.89%	36.12%
Common Stock	$48.00K	$42.00K
YoY Change	14.29%	5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$166.6M	$155.1M
YoY Change
Total Liabilities & Shareholders Equity	$223.8M	$172.5M
YoY Change	29.69%	-16.77%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$27.94M	-$25.65M
YoY Change	8.94%	26.63%
Depreciation, Depletion And Amortization	$228.0K	$273.0K
YoY Change	-16.48%	50.83%
Cash From Operating Activities	-$18.30M	-$26.50M
YoY Change	-30.96%	22.97%
INVESTING ACTIVITIES
Capital Expenditures	$17.00K	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$17.00K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	400.0K
YoY Change	-100.0%	194.12%
NET CHANGE
Cash From Operating Activities	-18.30M	-26.50M
Cash From Investing Activities	-17.00K	0.000
Cash From Financing Activities	0.000	400.0K
Net Change In Cash	-18.31M	-26.10M
YoY Change	-29.84%	15.64%
FREE CASH FLOW
Cash From Operating Activities	-$18.30M	-$26.50M
Capital Expenditures	$17.00K	$0.00
Free Cash Flow	-$18.31M	-$26.50M
YoY Change	-30.89%	29.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001069530
	dei	Entity Registrant Name EntityRegistrantName	CASSAVA SCIENCES INC
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47976166
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47976166
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42236919
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42236919
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	-0
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2024Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41905
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	91-1911336
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6801 N. Capital of Texas Highway, Building 1; Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78731
	dei	City Area Code CityAreaCode	512
	dei	Local Phone Number LocalPhoneNumber	501-2444
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	SAVA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48110475
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148978000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121136000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	40000000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13571000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8497000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	202549000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	129633000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21135000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21854000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	69000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	176000	usd
CY2024Q3	us-gaap	Assets Assets	223753000	usd
CY2023Q4	us-gaap	Assets Assets	151663000	usd
CY2024Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	52244000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	10573000	usd
CY2024Q3	sava	Accrued Development Expense Current AccruedDevelopmentExpenseCurrent	2543000	usd
CY2023Q4	sava	Accrued Development Expense Current AccruedDevelopmentExpenseCurrent	3037000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1950000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	200000	usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	297000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	385000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	57034000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14195000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	80000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2024Q3	us-gaap	Liabilities Liabilities	57114000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14195000	usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	48000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	42000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	544105000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	518195000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-377514000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380769000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	166639000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	137468000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	223753000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	151663000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17676000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23603000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49107000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70692000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12947000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4276000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	62852000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12476000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	30623000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	27879000	usd
	us-gaap	Operating Expenses OperatingExpenses	111959000	usd
	us-gaap	Operating Expenses OperatingExpenses	83168000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-30623000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-27879000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-111959000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-83168000	usd
CY2024Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2618000	usd
CY2023Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2005000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6710000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	6254000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	223000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	321000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	616000	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-108183000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-27943000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3255000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47976000
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42002000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45734000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41845000
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-27943000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3255000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
CY2024Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-0	usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-0	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	43793000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-0	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-27943000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25651000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-40538000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-76298000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47976000
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42002000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46101000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41845000
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.82
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	227539000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	64000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-24271000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	204005000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	889000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-26376000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	179353000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	464000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	155115000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	137468000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	113363000	usd
CY2024Q1	sava	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	22160000	usd
CY2024Q1	sava	Adjustments To Additional Paid In Capital Derecognition Of Warrant Liabilities Upon Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants	4954000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	25043000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	78597000	usd
CY2024Q2	sava	Stock Issued During Period Value Warrant Exercises StockIssuedDuringPeriodValueWarrantExercises	101392000	usd
CY2024Q2	sava	Adjustments To Additional Paid In Capital Derecognition Of Warrant Liabilities Upon Exercise Of Warrants AdjustmentsToAdditionalPaidInCapitalDerecognitionOfWarrantLiabilitiesUponExerciseOfWarrants	226000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	6155000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	188974000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-27943000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	166639000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3255000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10547000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2457000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-108183000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Depreciation Depreciation	724000	usd
	us-gaap	Depreciation Depreciation	817000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	148000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	357000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5074000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2377000	usd
	sava	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	-0	usd
	sava	Increase Decrease In Operating Lease Right Of Use Assets And Liabilities Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilitiesNet	17000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	41671000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5815000	usd
	sava	Increase Decrease In Development Expense IncreaseDecreaseInDevelopmentExpense	-494000	usd
	sava	Increase Decrease In Development Expense IncreaseDecreaseInDevelopmentExpense	5064000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1750000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	17000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-298000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55664000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59709000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	373000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-373000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	123552000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1417000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	123552000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1417000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	67842000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-58665000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121136000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	201015000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	188978000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	142350000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148978000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142350000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	40000000	usd
CY2023Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	0	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	188978000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	142350000	usd
	sava	Issuance Of Warrants Resulting In Recognition Of Warrant Liabilities IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities	113363000	usd
	sava	Issuance Of Warrants Resulting In Recognition Of Warrant Liabilities IssuanceOfWarrantsResultingInRecognitionOfWarrantLiabilities	0	usd
	sava	Derecognition Of Warrant Liabilities Through Exercises DerecognitionOfWarrantLiabilitiesThroughExercises	-5180000	usd
	sava	Derecognition Of Warrant Liabilities Through Exercises DerecognitionOfWarrantLiabilitiesThroughExercises	0	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-377500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q1	sava	Class Of Warrant Or Right Fair Value Of Common Stock Warrants Per Warrant ClassOfWarrantOrRightFairValueOfCommonStockWarrantsPerWarrant	6.71
CY2024Q2	sava	Class Of Warrant Or Right Redemption Price Per Share ClassOfWarrantOrRightRedemptionPricePerShare	0.001
CY2024Q2	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-27943000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3255000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47976000
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42002000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45734000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41845000
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.58
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.61
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-27943000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-25651000	usd
	us-gaap	Net Income Loss NetIncomeLoss	3255000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-76298000	usd
CY2024Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
CY2023Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
	us-gaap	Dilutive Securities DilutiveSecurities	-43793000	usd
	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-27943000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-25651000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-40538000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-76298000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47976000
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42002000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45734000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	41845000
CY2024Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	367000
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47976000
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42002000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46101000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	41845000
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.58
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.61
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.82
CY2024Q3	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	1100000	usd
CY2023Q3	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	0	usd
	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	9900000	usd
	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	100000	usd
CY2024Q3	sava	Insurance Settlements Maximum Recovery Limit InsuranceSettlementsMaximumRecoveryLimit	10000000	usd
	sava	Prepaid Expenses And Other Current Assets Text Bock PrepaidExpensesAndOtherCurrentAssetsTextBock	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">3.</em> Prepaid Expenses and Other Current Assets</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Prepaid expenses and other current assets at <em style="font: inherit;"> September 30, 2024</em> and <em style="font: inherit;"> December 31, 2023</em> consisted of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">September 30,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31,</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2024</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2023</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,198</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">759</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Contract research organization and other deposits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5,906</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,489</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,275</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">962</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">Insurance recoveries</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">192</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">287</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13,571</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,497</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	1198000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	759000	usd
CY2024Q3	us-gaap	Deposit Contracts Assets DepositContractsAssets	5906000	usd
CY2023Q4	us-gaap	Deposit Contracts Assets DepositContractsAssets	6489000	usd
CY2024Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	1275000	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	962000	usd
CY2024Q3	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	5000000	usd
CY2023Q4	us-gaap	Insurance Settlements Receivable Current InsuranceSettlementsReceivableCurrent	0	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	192000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	287000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13571000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8497000	usd
CY2024Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	288000	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	583000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1005000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1699000	usd
CY2024Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	226000	usd
CY2023Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	360000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	684000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1083000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	62000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	223000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	321000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	616000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24143000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24138000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3008000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2284000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21135000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21854000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	228000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	273000	usd
	us-gaap	Depreciation Depreciation	724000	usd
	us-gaap	Depreciation Depreciation	817000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1387000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1346000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1318000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1170000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	69000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	176000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	119000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	148000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	357000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	31000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	18000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	14000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	6000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	69000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3039029
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1273000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	208000
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4104029
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.79
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y1M6D
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	45200000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	214124
CY2023Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	464000	usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	495299
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1417000	usd
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5609000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	949000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10547000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2457000	usd
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note <em style="font: inherit;">11.</em> Contingencies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">The Company is, and from time to time, the Company <em style="font: inherit;"> may </em>become, involved in litigation or other legal proceedings and claims, including U.S. government inquiries, investigations and Citizen Petitions submitted to FDA. In addition, the Company has received, and from time to time <em style="font: inherit;"> may </em>receive, inquiries from government authorities relating to matters arising from the ordinary course of business. The outcome of these proceedings is inherently uncertain. Regardless of outcome, legal proceedings can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors. At this time, <em style="font: inherit;">no</em> assessment can be made as to their likely outcome or whether the outcome will be material to the Company other than as disclosed below. The Company believes that its total provisions for legal matters are adequate based upon currently available information.</p> <p style="margin: 0pt 0pt 0pt -9pt; font-size: 10pt; font-family: "Times New Roman";"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -2pt;"><i>Update on Government Investigations</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">Beginning in <em style="font: inherit;"> August 2021, </em>the Company has received subpoenas, a Civil Investigative Demand (“CID”) and other requests for documents and information from the Department of Justice (“DOJ”) and document requests from the SEC, each seeking corporate information and documents concerning the research and development of simufilam and/or SavaDx. The Company has been providing documents and information in response to these subpoenas, the CID and requests for information.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -4pt; text-indent: 25pt;">On <em style="font: inherit;"> September 26, 2024, </em>the Company announced that it had reached a settlement with the SEC resolving the SEC investigation of the Company’s disclosures regarding its Phase <em style="font: inherit;">2b</em> clinical trial of simufilam for the treatment of Alzheimer’s disease (the “Phase <em style="font: inherit;">2b</em> Study”) and related matters. The SEC also agreed to a settlement with <em style="font: inherit;">two</em> former senior employees of the Company. The settlements with the Company and its former senior employees are subject to final approval by a U.S. District Court. The SEC’s complaint alleges that certain disclosures by the Company regarding the Phase <em style="font: inherit;">2b</em> Study violated certain federal securities laws and SEC rules, including negligence-based disclosure violations of Sections <em style="font: inherit;">17</em>(a)(<em style="font: inherit;">2</em>) and <em style="font: inherit;">17</em>(a)(<em style="font: inherit;">3</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended (the “Securities Act”), as well as recordkeeping and reporting requirements under the Securities Exchange Act of <em style="font: inherit;">1934,</em> as amended (the “Exchange Act”). The complaint alleges that the Company’s SEC reports and other public statements regarding the Phase <em style="font: inherit;">2b</em> Study negligently contained materially misleading statements and omissions. The SEC’s allegations with respect to the Company’s <em style="font: inherit;">two</em> former employees relate to these employees’ roles in such disclosures. Under its settlement, the Company has consented to a permanent injunction against future violations of Section <em style="font: inherit;">17</em>(a) of the Securities Act, Section <em style="font: inherit;">13</em>(a)(<em style="font: inherit;">1</em>) of the Exchange Act and Rules <em style="font: inherit;">12b</em>-<em style="font: inherit;">20,</em> <em style="font: inherit;">13a</em>-<em style="font: inherit;">1,</em> <em style="font: inherit;">13a</em>-<em style="font: inherit;">11</em> and <em style="font: inherit;">13a</em>-<em style="font: inherit;">13</em> under the Exchange Act. In addition, the Company has agreed to pay a civil monetary penalty of <em style="font: inherit;">$40</em> million, which is classified in accounts payable and accrued expenses on its consolidated balance sheet as of <em style="font: inherit;"> September 30, 2024.</em></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 25pt;">The Company continues to cooperate with the DOJ related to requests for documents and information, including those related to conduct alleged in the indictment of Dr. Hoau-Yan Wang announced by DOJ on <em style="font: inherit;"> June 28, 2024. </em>The Company cannot predict the outcome or impact of ongoing matters, including whether a government authority <em style="font: inherit;"> may </em>pursue an enforcement action against the Company or others. The Company does <em style="font: inherit;">not</em> at this time anticipate, however, that DOJ will bring criminal charges against or seek a criminal resolution with the Company.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt;"><i>Securities Class Actions and Shareholder Derivative Actions</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Between <em style="font: inherit;"> August 27, 2021 </em>and <em style="font: inherit;"> October 26, 2021, </em><span style="-sec-ix-hidden:c120064488">four</span> putative class action lawsuits were filed alleging violations of the federal securities laws by the Company and certain named officers. The complaints rely on allegations contained in Citizen Petitions submitted to FDA and allege that various statements made by the defendants regarding simufilam were rendered materially false and misleading. The Citizen Petitions were all subsequently denied by FDA. These actions were filed in the U.S. District Court for the Western District of Texas. The complaints seek unspecified compensatory damages and other relief on behalf of a purported class of purchasers.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> June 30, 2022, </em>a federal judge consolidated the <span style="-sec-ix-hidden:c120064489">four</span> class action lawsuits into <span style="-sec-ix-hidden:c120064490">one</span> case and appointed a lead plaintiff and a lead counsel. Lead plaintiff filed a consolidated amended complaint on <em style="font: inherit;"> August 18, 2022 </em>on behalf of a putative class of purchasers of the Company’s securities between <em style="font: inherit;"> September 14, 2020 </em>and <em style="font: inherit;"> July 26, 2022. </em>On <em style="font: inherit;"> May 11, 2023, </em>the court dismissed with prejudice plaintiffs’ claims against defendant Nadav Friedmann, PhD, MD, our former Chief Medical Officer and a Company director, who is now deceased, but otherwise denied defendants’ motion to dismiss. Defendants filed an answer to the consolidated amended complaint on <em style="font: inherit;"> July 3, 2023. </em>On <em style="font: inherit;"> February 22, 2024, </em>plaintiffs filed a motion to supplement their complaint to extend the putative class period through <em style="font: inherit;"> October 12, 2023. </em>The court granted that Motion on <em style="font: inherit;"> June 12, 2024, </em>and plaintiffs filed a supplemental complaint on <em style="font: inherit;"> June 13, 2023. </em>On <em style="font: inherit;"> March 13, 2024, </em>plaintiffs filed a Motion for Class Certification. The Company has opposed that Motion.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> November 4, 2021, </em>a related shareholder derivative action was filed, purportedly on behalf of the Company, in the U.S. District Court for the Western District of Texas, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company’s Board. This complaint relies on the allegations made in Citizen Petitions that were submitted to (and subsequently denied by) FDA. The complaint alleges, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative case seeks, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendants’ alleged wrongful conduct. Although the plaintiff in this derivative case does <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. Between <em style="font: inherit;"> November 4, 2021 </em>and <em style="font: inherit;"> June 20, 2023, </em><span style="-sec-ix-hidden:c120064493">four</span> additional shareholder derivative actions were filed alleging substantially similar claims, <span style="-sec-ix-hidden:c120064494">two</span> in the U.S. District Court for the Western District of Texas, <span style="-sec-ix-hidden:c120064495">one</span> in Texas state court (Travis County District Court) and <span style="-sec-ix-hidden:c120064496">one</span> in the Delaware Court of Chancery. On <em style="font: inherit;"> July 5, 2022, </em>the <span style="-sec-ix-hidden:c120064497">three</span> actions in the Western District of Texas were consolidated into a single action. All of the foregoing actions are currently stayed pending further developments in the consolidated securities action described above. On <em style="font: inherit;"> November 9, 2023, </em>another shareholder derivative action alleging substantially similar claims was filed in the U.S. District Court for the Western District of Texas. The parties to that case expect that it will be consolidated into the existing consolidated federal court shareholder derivative action.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> February 2, 2024, </em>a putative class action lawsuit was filed, purportedly on behalf of the Company, alleging violations of the federal securities law by the Company and certain named officers. The complaint relies on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a scientific collaborator of the Company at City University of New York. The complaint alleges that various statements made by the defendants regarding simufilam were rendered materially false and misleading by this article. The action was filed in the U.S. District Court for the Northern District of Illinois. The complaint seeks unspecified compensatory damages and other relief on behalf of a purported class of purchasers of the Company’s securities between <em style="font: inherit;"> August 18, 2022 </em>and <em style="font: inherit;"> October 12, 2023. </em>On <em style="font: inherit;"> May 28, 2024, </em>the Northern District of Illinois transferred this action to the Western District of Texas.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">Beginning on <em style="font: inherit;"> March 18, 2024, </em><span style="-sec-ix-hidden:c120064499">two</span> related shareholder derivative actions were filed, purportedly on behalf of the Company, in the U.S. District Court for the Northern District of Illinois, asserting claims under the U.S. securities laws and state fiduciary duty laws against certain named officers and the members of the Company’s Board. The complaints rely on an <em style="font: inherit;"> October 12, 2023 </em>article that describes a purported leaked report of alleged scientific misconduct by a scientific collaborator of the Company at City University of New York. The complaints allege, among other things, that the individual defendants exposed the Company to unspecified damages and securities law liability by causing it to make materially false and misleading statements, in violation of the U.S. securities laws and in breach of their fiduciary duties to the Company. The derivative cases seek, among other things, to recover unspecified compensatory damages on behalf of the Company arising out of the individual defendant’s alleged wrongful conduct. Although the plaintiffs in these derivative cases do <em style="font: inherit;">not</em> seek relief against the Company, the Company has certain indemnification obligations to the individual defendants. On <em style="font: inherit;"> September 6, 2024, </em>these <span style="-sec-ix-hidden:c120064501">two</span> cases were consolidated and stayed pending further developments in the shareholder class action initially filed in the Northern District of Illinois on <em style="font: inherit;"> February 2, 2024.</em></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">The Company disputes the allegations and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> August 19, 2022, </em>a shareholder derivative action was filed, purportedly on behalf of the Company, in the Delaware Court of Chancery, asserting claims under state fiduciary duty laws against certain named officers and members of the Company’s Board. The complaint alleges, among other things, that the individual defendants breached their fiduciary duties by approving the CIB Plan in <em style="font: inherit;"> August 2020. </em>The complaints seek unspecified compensatory damages and other relief. On <em style="font: inherit;"> January 6, 2023, </em>the plaintiffs filed an amended complaint. Defendants filed a partial answer to the amended complaint on <em style="font: inherit;"> March 10, 2023, </em>and moved to partially dismiss the amended complaint on <em style="font: inherit;"> March 14, 2023.</em></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> May 28, 2024, </em>the parties entered into a Stipulation and Agreement of Settlement, Compromise, and Release (the “Stipulation”) to resolve the action. The Stipulation and exhibits thereto, including the proposed Notice of Pendency of Settlement of Class and Derivative Action (the “Notice”) and [Proposed] Scheduling Order with Respect to Notice and Settlement Hearing (the “Scheduling Order”), were filed in the Delaware Court of Chancery on <em style="font: inherit;"> May 28, 2024. </em>The Stipulation is subject to final approval by the Delaware Court of Chancery. The Stipulation, if finally approved, will cause the dismissal with prejudice of the Action.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;">On <em style="font: inherit;"> June 26, 2024, </em>the Delaware Court of Chancery entered the Scheduling Order, which includes approval of the Notice. Resolution of the Action is subject to approval from the Delaware Court of Chancery. The Delaware Court of Chancery held a settlement hearing on <em style="font: inherit;"> September 9, 2024. </em>Supplemental briefing followed and the matter remains under submission.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt -2pt; text-indent: 18pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt;"><i>Anti-SLAPP Lawsuit</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -9pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 18pt;">On <em style="font: inherit;"> August 6, 2024, </em>a lawsuit was filed in the District Court for the Southern District of New York which, as amended, asserts claims, including a claim under the New York Anti-SLAPP Law, against the Company and against two former officers to whom the Company has certain indemnification obligations. The amended complaint seeks costs and damages relating to a defamation action filed by the Company against the plaintiffs and subsequently dismissed voluntarily and without prejudice by the Company. The Company will defend the lawsuit vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with this lawsuit.</p>
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	16895000
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	113363000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
sava-20240930_cal.xml	Edgar Link	unprocessable
0001437749-24-033944-index-headers.html	Edgar Link	pending
0001437749-24-033944-index.html	Edgar Link	pending
0001437749-24-033944.txt	Edgar Link	pending
0001437749-24-033944-xbrl.zip	Edgar Link	pending
a03.jpg	Edgar Link	pending
cab1ac4300e0img001.jpg	Edgar Link	pending
chart_2.jpg	Edgar Link	pending
ex_717369.htm	Edgar Link	pending
ex_717370.htm	Edgar Link	pending
ex_717371.htm	Edgar Link	pending
fig5.jpg	Edgar Link	pending
figure01.jpg	Edgar Link	pending
figure03.jpg	Edgar Link	pending
figure04.jpg	Edgar Link	pending
figure4b02.jpg	Edgar Link	pending
figure5b02.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sava-20240930.xsd	Edgar Link	pending
sava20240930_10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending
slide05.jpg	Edgar Link	pending
sava-20240930_def.xml	Edgar Link	unprocessable
sava-20240930_lab.xml	Edgar Link	unprocessable
sava-20240930_pre.xml	Edgar Link	unprocessable
sava20240930_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SAVA
CASSAVA SCIENCES INC Stock $sava

2024 Q4 Form 10-Q Financial Statement

#000143774924033944 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SAVA CASSAVA SCIENCES INC Stock $sava

2024 Q4 Form 10-Q Financial Statement

#000143774924033944 Filed on November 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SAVA
CASSAVA SCIENCES INC Stock $sava